ChemicalBook >> CAS DataBase List >>Levofloxacin hydrochloride

Levofloxacin hydrochloride

CAS No.
100986-85-4
Chemical Name:
Levofloxacin hydrochloride
Synonyms
Levofloxacin;LEVOFLOXACIN HCL;Ophthalmic;levoflaxacin;Cravit;Levaquin;L-Ofloxacin;Levofloxacin base;7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)-;LVFX
CBNumber:
CB4122906
Molecular Formula:
C18H20FN3O4
Molecular Weight:
361.37
MDL Number:
MFCD00865049
MOL File:
100986-85-4.mol
MSDS File:
SDS
Modify Date:2022-11-11 13:01:00

Levofloxacin hydrochloride Properties

Melting point 218°C
Boiling point 572℃
Density 1.48±0.1 g/cm3(Predicted)
Flash point >110°(230°F)
storage temp. Keep in dark place,Sealed in dry,2-8°C
solubility chloroform: soluble10mg/mL
form powder
pka 5.19±0.40(Predicted)
color white to faint yellow
optical activity [α]20/D -104±4° in chloroform
Water Solubility Slightly soluble in water or methanol. Soluble in glacial acetic acid or dichloromethane
Sensitive Light Sensitive
Merck 14,6771
BRN 7327015
InChIKey GSDSWSVVBLHKDQ-JTQLQIEISA-N
CAS DataBase Reference 100986-85-4(CAS DataBase Reference)
NCI Dictionary of Cancer Terms levofloxacin; ophthalmic
FDA UNII 6GNT3Y5LMF
NCI Drug Dictionary Levaquin
ATC code J01MA12,S01AE05
EPA Substance Registry System 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3S)- (100986-85-4)

Pharmacokinetic data

Protein binding 30-40%
Excreted unchanged in urine >85%
Volume of distribution 1.1-1.5(L/kg)
Biological half-life 6-8 (5-7 nebulised) / 35

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07,GHS08
Signal word  Danger
Hazard statements  H302-H317-H334
Precautionary statements  P261-P264-P270-P280-P301+P312-P302+P352
Hazard Codes  Xn
Risk Statements  22-42/43-68-20/21/22-64-63
Safety Statements  26-36/37/39-36
RIDADR  UN 1648 3 / PGII
WGK Germany  3
RTECS  UU8815550
HS Code  29349990
Toxicity LD50 oral in rat: 1478mg/kg

Levofloxacin hydrochloride price More Price(48)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich 28266 Levofloxacin 98.0-102.0% anhydrous basis (HPLC) 100986-85-4 1g $46.6 2022-05-15 Buy
Sigma-Aldrich 28266 Levofloxacin 98.0-102.0% anhydrous basis (HPLC) 100986-85-4 10g $105 2022-05-15 Buy
TCI Chemical L0193 Levofloxacin >98.0%(HPLC) 100986-85-4 5g $38 2022-04-27 Buy
TCI Chemical L0193 Levofloxacin >98.0%(HPLC) 100986-85-4 25g $112 2022-04-27 Buy
Alfa Aesar J66943 Levofloxacin, 98% 100986-85-4 1g $20 2022-04-27 Buy
Product number Packaging Price Buy
28266 1g $46.6 Buy
28266 10g $105 Buy
L0193 5g $38 Buy
L0193 25g $112 Buy
J66943 1g $20 Buy

Levofloxacin hydrochloride Chemical Properties,Uses,Production

Description

Levofloxacin, the optically active S-isomer of the fluoroquinolone antibiotic ofloxacin, is two to four times more potent than ofloxacin with reportedly less side effects in treating infections of the lower respiratory and urinary tract, prostate infections and sexually transmitted diseases. It has broad and potent antibacterial activity over common Grampositive and -negative aerobic pathogens and obligate anaerobes. Different from the cephem antibiotics, levofloxacin is unique in its marked selectivity against members of the family Enterobacteriaceae and its negligible effect on predominant anaerobes. Levofloxacin also exhibits satisfactory antimicrobial effects in surgical infections and it may be used for treatment of gastrointestinal infections such as traveler’s diarrhea associated with the pathogenic Enterobacteriaceae.

Chemical Properties

Slight yellow powder

Originator

Daiichi (Japan)

Uses

Levofloxacin is a broad-spectrum antibiotic used in pharmacokinetic?, antibiotic resistance?, and resistance prevention?studies. Levofloxacin is active against Gram-positive and Gram-negative bacteria. It inhibits DNA gyrase (type II topoisomerase) and topoisomerase IV, thereby inhibiting cell division.

Uses

Antibacterial.

Manufacturing Process

()-3-Acetoxymethyl-7,8-difluoro-2,3-dihydro-4H-[1,4]benzoxazine (m.p. 73- 74°C) was synthesized by hydrogenation of a compound prepared from 2,3- difluoro-6-nitrophenol, 1-acetoxy-3-chloro-2-propane and potassium iodide. The hydrogenation was carried out on Raney nickel. The resulting compound was dissolved in THF, and 3,5-dinitrobenzoyl chloride and pyridine were added thereto, followed by heating at 60°C for 3 hours. The mixture was concentrated, and the concentrate was dissolved in ethyl acetate, washed successively with diluted hydrochloric acid, an aqueous solution of sodium bicarbonate and water, dried over anhydrous sodium sulfate and concentrated. Addition of n-hexane to the concentrate caused precipitation of yellow crystals of a racemate. The yield of 3,5-dinitrobenzoyl derivative of the ()-3- acetoxymethyl-7,8-difluoro-2,3-dihydro-4H-[1,4]benzoxazine 3.93 g.
To 2.0 ml of Amberlite XAD 7 was added 2.0 ml of a 0.05 M phosphoric acid buffer (pH 7.0) having dissolved therein 20 mg of lipoprotein lipase, and the system was allowed to stand at room temperature for 18 hours to thereby adsorb the enzyme onto the resin. The resin was filtered. A solution of 250 mg of 3,5-dinitrobenzoyl derivative of ()-3-acetoxymethyl-7,8-difluoro-2,3- dihydro-4H-[1,4]benzoxazine as a substrate in 25 ml of a mixed solvent of benzene and n-hexane (4:1 by volume) was added to the resin, followed byallowing to react at 37°C for 4 hours. It was obtained 117 mg of a 3,5- dinitrobenzoyl derivative of the (-)-3-acetoxymethyl-7,8-difluoro-2,3-dihydro- 4H-[1,4]benzoxazine and 65 mg of a derivative of the (-)-3-acetoxymethyl- 7,8-difluoro-2,3-dihydro-4H-[1,4]benzoxazine.
In 135 ml THF was dissolved 3.03 g of a 3,5-dinitrobenzoyl derivative of (-)- 3-acetoxymethyl-7,8-difluoro-2,3-dihydro-4H-[1,4]benzoxazine, and 135 ml of ethanol and 30 ml of 1.0 N potassium hydroxide were added to the solution. After 30 min 3 ml of acetic acid was added thereto for neutralization. The mixture was concentrated. The solid was subjected to column chromatography using 40 g of silica gel and eluted with chloroform/methanol to obtain 1.17 g of (-)-7,8-difluoro-2,3-dihydro-3-hydroxymethyl-4H-[1,4]benzoxazine; [α]D22 = -14.1° (c = 1.80, CHCl3).
To 1.17 g of (-)-7,8-difluoro-2,3-dihydro-3-hydroxymethyl-4H-[1,4] benzoxazine was added 2.77 g of thionyl chloride in pyridine. The reaction mixture was concentrated and the concentrate was subjected to column chromatography using 40 g of silica gel and eluted with chloroform to obtain 1.18 g of the reaction product as a colorless oily product. This product was dissolved in 30 ml of dimethyl sulfoxide, and 0.41 g of sodium borohydride was added thereto, followed by heating at 80-90°C for 1 hour. The reaction mixture was dissolved in 500 ml of benzene, washed with water to remove the dimethyl sulfoxide, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The concentrate was subjected to column chromatography using 40 g of silica gel and eluted with benzene to obtain 0.80 g of (-)-7,8-difluoro-2,3-dihydro-3-methyl-4H-[1,4]benzoxazine as a colorless oily product; [α]D25 = -9.6° (c = 2.17, CHCl3). Optical Purity: >99% e.e.
To 1.13 g of (-)-7,8-difluoro-2,3-dihydro-3-methyl-4H-[1,4]benzoxazine was added 1.58 g of diethyl ethoxymethylenemalonate, and the mixture was stirred at 130-140°C for 70 min. The reaction mixture was subjected to column chromatography using 50 g of silica gel and eluted with chloroform to obtain 2.47 g of diethyl [(-)-7,8-difluoro-3-methyl-2,3-dihydro-4H-[1,4] benzoxazin-4-yl]methylenemalonate. This product was dissolved in 5 ml of acetic anhydride, and 10 ml of a mixture of acetic anhydride and concentrated sulfuric acid (2/1 by volume) with stirring under ice-cooling, followed by stirring at 50-60°C for 40 min. To the reaction mixture were added ice and an aqueous solution of sodium bicarbonate, and the product was extracted three times with 150 ml portions of chloroform. The combined extract was washed with water, dried over anhydrous sodium sulfate and concentrated. The precipitate was washed with a small amount of diethyl ether to yield 1.32 g of (-)-ethyl 9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4] benzoxazine-6-carboxylate.
In 12 ml of acetic acid was dissolved 1.20 g of the resulting compound, and 25 ml of concentrated hydrochloric acid was added, followed by refluxing at 120-130°C for 90 min. Upon allowing the reaction mixture to stand at room temperature, colorless crystals were precipitated, which were collected by filtration and washed successively with a small amount of water, ethanol and diethyl ether to obtain 0.96 g of (-)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro- 7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid.
In 30 ml of diethyl ether was suspended 324 mg of the resulting compound,and a large excess of boron trifluoride ethyl etherate was added thereto, followed by stirring at room temperature for 30 min to form a chelate compound. The product was collected by filtration and washed with a small amount of diethyl ether to obtain 373 mg of a powder. The powder was dissolved in 7 ml of dimethyl sulfoxide, and 136 mg of N-methylpiperazine and 228 mg of triethylamine were added thereto, followed by stirring at room temperature for 17 hours. The reaction mixture was concentrated to dryness under reduced pressure, and to the solid were added 15 ml of 95% methanol and 0.31 ml of triethylamine. The resulting mixture was refluxed for 3 hours. The reaction mixture was concentrated under reduced pressure, and the residue was filtered and washed successively with a small amount of ethanol and diethyl ether to obtain 350 mg of a white powder. Recrystallization from a mixed solvent of ethanol and thick aqueous ammonia gave 230 mg of S-(-)- ofloxacin (Levofloxacin).
Melting Point: 225-227°C (with decomposition); [α]D23 = -76.9° (c = 0.39, 0.05 N NaOH).

brand name

Iquix (Sanofi Winthrop); Levaquin (Ortho-McNeil); Quixin (Sanofi Winthrop);Cravit.

Therapeutic Function

Antibacterial

Antimicrobial activity

Levofloxacin is the active component of ofloxacin; d-ofloxacin is without significant antibacterial activity. It exhibits good activity in vitro against Gram-positive cocci (including Str. pneumoniae), Enterobacteriaceae, some fastidious Gram-negative bacilli and Ps. aeruginosa as well as chlamydiae, Mycoplasma pneumoniae, L. pneumophila and M. tuberculosis. MICs for Acinetobacter spp. and Sten. maltophilia are 0.06–0.25 and 0.5–2.0 mg/L, respectively. Activity against anaerobes is moderate to low.

General Description

Chemical structure: quinolone

Pharmaceutical Applications

For molecular weight and structure, see ofloxacin . Levofloxacin is the l-isomer of ofloxacin.

Pharmacokinetics

Oral absorption: >95%
Cmax 500 mg oral: c. 5 mg/L after 1.5–2 h
750 mg oral: c. 8 mg/L after 1.5–2 h
500 mg intravenous (90-min infusion): c. 6 mg/L end infusion
750 mg intravenous (90-min infusion) :c. 12 mg/L end infusion
Plasma half-life :6–8 h
Volume of distribution:0.6–0.8 L/kg
Plasma protein binding: <25%
Co-administration with antacids, calcium, sucralfate and heavy metals decreases bioavailability and AUC. No interactions with warfarin or theophylline have been observed. Co-administration of a non-steroidal anti-inflammatory drug may increase the risk of convulsions. It undergoes limited metabolism and is primarily eliminated unchanged in urine by both glomerular filtration and tubular secretion. The free AUC:MIC ratio for Str. pneumoniae increases from about 55 to 70 when the daily dosage is raised from 500 mg to 750 mg.
It is stable in plasma and does not revert to d-ofloxacin. It undergoes limited metabolism and is primarily eliminated unchanged in the urine. Renal clearance in excess of the glomerular filtration rate suggests that tubular secretion also occurs. Concomitant administration of either cimetidine or probenecid reduces renal clearance by approximately onethird. Clearance is reduced and half-life is prolonged in patients with impaired renal function (creatinine clearance <50 mL/min) requiring dosage adjustment in such patients.

Clinical Use

Acute bacterial sinusitis
Acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia
Uncomplicated and complicated skin and skin structure infections
Uncomplicated and complicated urinary infections including acute pyelonephritis
Chronic bacterial prostatitis

Side effects

Side effects have been reported in 6–7% of patients and include fever, rash and other events common to the group. Elderly patients are at increased risk of developing severe tendon disorders including rupture, a risk increased by concomitant corticosteroid therapy.

Drug interactions

Potentially hazardous interactions with other drugs Aminophylline and theophylline: possibly increased risk of convulsions. Analgesics: possibly increased risk of convulsions with NSAIDs. Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone - avoid. Anticoagulants: anticoagulant effect of coumarins and phenindione enhanced. Antimalarials: manufacturer advises avoid concomitant use with artemether and lumefantrine. Ciclosporin: half-life of ciclosporin increased by 33%; increased risk of nephrotoxicity. Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide. Tacrolimus: may increase tacrolimus concentration.

Metabolism

Levofloxacin is metabolised to a very small extent, the metabolites being desmethyl-levofloxacin and levofloxacin N-oxide. These metabolites account for <5% of the dose and are excreted in urine. Excretion is primarily by the renal route

Global( 606)Suppliers
Supplier Tel Email Country ProdList Advantage
Wuhan Fortuna Chemical Co., Ltd
+86-27-59207850 +86-13986145403 info@fortunachem.com China 3384 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512 info@tianfuchem.com China 21975 55
Hangzhou FandaChem Co.,Ltd.
+8615858145714 fandachem@gmail.com China 9377 55
Guangzhou PI PI Biotech Inc
+86-020-81716320 +86-18371201331 Sales@pipitech.com China 3635 55
Hubei XinRunde Chemical Co., Ltd.
+8615102730682 bruce@xrdchem.cn CHINA 566 55
Hefei TNJ Chemical Industry Co.,Ltd.
0551-65418679 info@tnjchem.com China 2990 55
career henan chemical co
+86-0371-86658258 sales@coreychem.com China 29922 58
Shaanxi Yikanglong Biotechnology Co., Ltd.
17791478691 yklbiotech@163.com CHINA 296 58
Zhejiang ZETian Fine Chemicals Co. LTD
18957127338 stella@zetchem.com China 2116 58
Cangzhou Wanyou New Material Technology Co.,Ltd
18631714998 sales@czwytech.com CHINA 906 58

Related articles

  • Toxicity of Levofloxacin
  • Levofloxacin (Levaquins, Iquixs, Quixins) is a fluoroquinolone that is the optical S-(-) isomer of ofloxacin. It was originall....
  • Mar 15,2022

View Lastest Price from Levofloxacin hydrochloride manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
2022-09-24 Levofloxacin hydrochloride
100986-85-4
US $0.00-0.00 / KG 1KG 99% 500000kg Hebei Guanlang Biotechnology Co., Ltd.
2022-07-16 Levofloxacin hydrochloride
100986-85-4
US $0.00 / KG 1KG 99% 50000KG/month Hebei Mojin Biotechnology Co., Ltd
2022-02-25 Levofloxacin hydrochloride
100986-85-4
US $0.00 / KG 100g 98%+ 100kg WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD

Levofloxacin hydrochloride Spectrum

(s)-ofloxacin HR 355 RWJ 25213-097 Tavanic (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazin-yl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid LVFX RWJ 25213 Crarit S-(-)-9-Fluom-2,3-dihydrcr3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate [3S,(-)]-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid Levofloxacin (350 mg) Levofloxacin HeMihidrated Levofloxacin(Levaquin) LEVOFLOXACIN 99% 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylicacid,2,3-dihydro-9-fluoro-3-m dr3355 hemihydrate,(s)-ethyl-10-(4-methyl-1-piperazinyl)-7-oxo (3s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid monohydrochloride (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid Hemihydrate 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3S)- (9CI) Levofloxacin heMihydrate API acid Monohydrochloride (S)-9-fluoro-3-Methyl-10-(4-Methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Levofloxacin, HeMihydrate, USP (S)-9, 10-DIFLUORO-3-METHYL-7-OXO-7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID (S)-Ofloxacin,99%e.e. Levofloxacin solution Levofloxcin Levofloxacin hemyhydrate Erlotinib-d13 HCl Lelofloxacin Mesylate Levofloxacin Pharmaceutical Intermediates Levofloxacin base CAS 100986-85-4 Levofloxacin> Levofloxacin Levofloxacin Levofloxacin,>98% evofL 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3S)- RiMantadin Levofloxacin hydrochloride USP/EP/BP (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-1 0-oxo-4-oxa-1-azatricyclo[7.3.1.0,5,13]trideca-5(13 ),6,8,11-tetraene-11-carboxylic acid Veterinary Medicine Ofloxacin Powder CAS?100986-85-4) LevofloxacinQ: What is Levofloxacin Q: What is the CAS Number of Levofloxacin Q: What is the storage condition of Levofloxacin Q: What are the applications of Levofloxacin Levofloxacin (LVX), 98% 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)- Cravit Levaquin Levofloxacin L-Ofloxacin Ophthalmic LEVOFLOXACIN HCL Levofloxacin base levoflaxacin (-)-Ofloxacin 100986-85-4 1381997-71-0 138199-17-0 C18H2OFN3O412H2O